Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9241243 | 0.88 | POLB (0.39) | GPR84FFAR1FFAR4ALDH1A1HSD17B10 | |
| SCHEMBL606836 | 0.76 | POLB (0.38) | GPR84FFAR1FFAR4ALDH1A1HSD17B10 | |
| SCHEMBL15121367 | 0.70 | — | — | |
| SCHEMBL670063 | 0.69 | TERT (0.45) | KDM4ELMNAALDH1A1HSD17B10KMT2A | |
| SCHEMBL11607553 | 0.68 | ACE2 (0.36) | GPR84FFAR1 | |
| SCHEMBL942698 | 0.64 | POLB (0.40) | GPR84FFAR1FFAR4ALDH1A1HSD17B10 | |
| SCHEMBL6160340 | 0.63 | — | — | |
| SCHEMBL10632210 | 0.63 | — | — | |
| Oxanamide SCHEMBL546912 | 0.63 | — | — | |
| 1,6-Hexanediol SCHEMBL3993051 | 0.60 | FFAR3 (0.62) | GPR84FFAR1FFAR4KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198382-A1 | Oxiran carboxylic acids for the treatment of diabetes | HORST P.O. WOLF (DE) | 2002-12-26 | — | — | US | disclosed |
| US-6013666-A | ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION | Jew, Sang Sup (KR) | 2000-01-11 | — | — | US | disclosed |
| WO-1998000422-A1 | OXIRANE CARBOXYLIC ACID DERIVATIVE AND ITS MANUFACTURING METHOD | JEW SANG SUP (KR) | 1998-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198382-A1 | Oxiran carboxylic acids for the treatment of diabetes | GPR119, SLC5A2, SLC2A4 | GPR84 426/4885FFAR1 17/4885FFAR4 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.